Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UNIPROT:P39060 (endostatin)
 2,284 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

TAC-101 (4-[3,5-bis(trimethylsilyl)benzamido]benzoic acid) is a novel, synthetic retinoid that is effective against liver metastases of human gastrointestinal cancer cells such as the human stomach carcinoma line AZ-521 in animal models, and is currently in use in phase I cancer trials. However, the mechanism of its antimetastatic action is still poorly understood. Tumor metastasis depends on angiogenesis, and various retinoids have been found to exhibit antiangiogenic activity. Based on these findings we here examined the antiangiogenic effects of TAC-101. Oral administration of TAC-101 (2-8 mg/kg/day) resulted in a drastic suppression of the AZ-521 cell-induced angiogenesis in a mouse dorsal air sac assay system, compared to the vehicle alone. Immunohistochemical analysis with antibody against the endothelial marker CD31 revealed a significant reduction in microvessel density in liver metastases from animals treated with TAC-101 (8 mg/kg p.o.), compared to liver metastases from the untreated control animals. The ability of TAC-101 (8 mg/kg p.o.) to prevent experimental liver metastasis of AZ-521 cells in athymic nude mice was comparable with that of the known angiogenesis inhibitor TNP-470 (30 mg/kg s.c.). TAC-101 also affected angiogenesis in chorioallantoic membranes and some functions of endothelial cells associated with angiogenesis, whereas the retinoid failed to suppress AZ-521 cell proliferation directly. These data suggest that the TAC-101 is an orally active antiangiogenic agent and that this antiangiogenic property may contribute to its efficacy against liver metastasis of human stomach cancer cells.
 ...
PMID:A potential use of a synthetic retinoid TAC-101 as an orally active agent that blocks angiogenesis in liver metastases of human stomach cancer cells. 1171 48

The rate of the ligand-substitution reaction of nickel(II)-TAC chelate (NiR(2)) with EDTA (Y) and 1,10-phenanthroline (X) has been determined spectrophotometrically in 20% v v dioxan over the pH range 5.7-6.3 at mu = 0.1 (KNO(3)) and 25 +/- 1 degrees . The substitution reaction with EDTA proceeds through the following two pathways: NiR(2) + H(+) right harpoon over left harpoon NiR(+) + HR, and NiR(2) + H(2)O right harpoon over left harpoon NiR(OH) + HR, The reaction of NiR(+) or NiR(OH) with EDTA is the rate-determining step, and k(1) = 2.1 x 10(3) l .mole(-1) .sec(-1) and k(2) = 7.9 x 10(6) l .mole(-1) .sec(-1).The substitution reaction with 1,10-phenanthroline proceeds as follows: NiR(+) + X right harpoon over left harpoon NiRX(+) At higher concentrations of 1,10-phenanthroline the release of TAC from NiR(2) by hydrogen ion is the rate-determining step, and k(3) = 2.4 x 10(5) l .mole(-1). sec(-1). At lower concentrations of 1,10-phenanthroline -d[NiR(2)]/dt is proportional both to [H(+)] and [X]. The value k(4) = 5.1 x 10(4) l. mole(-1). sec(-1) was calculated by the use of the steady-state approximation for [NiRX(+)]. The substitution with 1,10-phenanthroline proceeds much faster than that with EDTA. By the addition of a small amount of 1,10-phenanthroline, Ni can be titrated with EDTA at 50 degrees, with TAC as an indicator.
 ...
PMID:Effects of auxiliary complex-forming agents on the rate of metallochromic indicator colour-change-III: mechanism of the colour change of tac in nickel-edta titrations. 1896 25